19 Oct Long-Term Cannabis Use Linked to Poorer Sleep on Wearable Trackers, Even When Users Report Sleeping Well
Cannabis/CBD Notice: Cannabis products are not FDA monitored or approved. Discuss your use of medicinal cannabis or CBD products with your healthcare provider before use. Dosing is variable and products may interfere with other medications, stimulants and alcohol. Do not use cannabis or CBD products if you are pregnant, nursing, or may become pregnant. Do not use cannabis products when driving or operating difficult or dangerous machinery. Keep out of reach of children. Children and pets should not be exposed to cannabis or CBD products.
MedicalResearch.com Interview with:
Thanh-Huyen T. Vu, MD, PhD
Research Associate Professor
Department of Preventive Medicine
Northwestern University Feinberg School of Medicine, Chicago, Illinois
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Cannabis is widely used and legal in many states. Many people believe that it helps them sleep better. However, few studies have tested whether cannabis use is associated with sleep—particularly sleep that is measured using devices rather than self-reported. Our study asked adults about their cannabis use multiple times over 35 years. And more recently, we measured sleep duration and quality using a wearable device similar to an Apple Watch or Fitbit and asked people to tell us about their sleep.
We found that adults who used cannabis regularly over a number of years had sleep that we would describe as lower quality—more frequent awakenings and with less time during their sleep period spent asleep. However, when asked, adults who used cannabis and those who didn't reported similar sleep patterns—which wasn't the case when we measured it.
Dr. Paller[/caption]
Amy S Paller, MD
Chair, Department of Dermatology
Director, Skin Biology and Diseases Resource-Based Center
Walter J. Hamlin Professor of Dermatology
Professor of Dermatology and Pediatrics (Dermatology)
Feinberg School of Medicine
Northwestern University
Dr. Paller discusses the FDA approval of Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis (eczema), whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
MedicalResearch.com: What is the background for this announcement? Would you briefly discuss what is meant by atopic dermatitis and how it affects children?
Response: “Atopic dermatitis, the most common form of eczema, is a chronic inflammatory disease that often appears as a rash on the skin. Moderate-to-severe atopic dermatitis is characterized by rashes that can potentially cover much of the body and can include intense, persistent itching, skin lesions and skin dryness, cracking, redness or darkness, crusting and oozing. Itch is one of the most burdensome symptoms for patients and can be debilitating.
This recent FDA approval expands the use of Dupilumab in the U.S. to include children aged 6 to 11 years with uncontrolled moderate-to-severe atopic dermatitis, making it the only biologic medicine approved for this use in this population. Dupilumab is also approved in the U.S. to treat patients aged 12 years and older with moderate-to-severe atopic dermatitis.
Moderate-to-severe atopic dermatitis can place a particularly substantial burden on young children aged 6 to 11 years and their families. Limited treatment options leave many of these children to cope with intense, unrelenting itch and skin lesions. Families of these children can spend countless hours helping them to manage their disease.” 
Dr. Gupta[/caption]
Ruchi Gupta MD MPH
Mary Ann & J Milburn Smith Senior Scientist in Child Health Research
Director, Science & Outcomes of Allergy & Asthma Research
Professor of Pediatrics & Medicine
Clinical Attending
Ann & Robert H. Lurie Children's Hospital of Chicago
Institute for Public Health and Medicine
Northwestern Feinberg School of Medicine
[caption id="attachment_47681" align="alignleft" width="125"]
Dr. Warren[/caption]
Christopher M. Warren, PhD
University of Southern California
Los Angeles, CA
MedicalResearch.com: What is the background for this study?
Response: Readers may be familiar with the so-called "top 8" food allergens (i.e. peanut, tree nut, cow's milk, fin fish, shellfish, egg, wheat and soy), which are responsible for the majority of food allergies in the US. However, in recent years increasing attention has been paid to sesame allergy, which evidence suggests can lead to anaphylaxis, frequently results in accidental exposure among affected patients, and is infrequently outgrown. Until now, only one 2010 study has systematically assessed the prevalence of sesame among both US children and adults. It concluded that sesame allergies were reported by approximately .1% of the US population.
However, this study, which surveyed a sample of approximately 5000 US households only captured 13 individuals with reported sesame allergy, which limited the authors' ability to draw more detailed conclusions about the specific characteristics of sesame allergy in the United States.